AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 7 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology has entered into a collaboration and license agreement with Merck & Co. Inc. for the research and development of products specific for a key target involved in disease mediated by HIV.
Under the terms of the five-year agreement, Merck will provide proprietary technology and experience in HIV biology and CAT will provide its proprietary human phage antibody libraries. Merck receives exclusive rights to prophylactic and therapeutic products developed in collaboration with CAT against the specified viral target. CAT will receive an upfront technology access fee from Merck, clinical development milestones, and royalties on the sale of products based on both human monoclonal antibodies and on nonantibody products validated using the CAT technology.
"This new alliance with Merck, a global leader in microbial ...